Navigation Links
Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
Date:8/7/2012

com/m/p/uk852bf4">http://www.media-server.com/m/p/uk852bf4.  Please allow extra time prior to the webcast to register, download and install any necessary audio software.  The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning today at 10:30 AM ET, at 1-888-286-8010 (U.S. callers) or +1-617-801-6888 (international), using passcode 11016101.

About InsmedInsmed Incorporated is a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, with a particular focus on orphan diseases.  Insmed's core expertise is the development of inhaled antibiotic therapy delivered via proprietary advanced liposomal pulmonary technology.  For more information, please visit http://www.insmed.com.

Investor Relations Contact:
Brian Ritchie – FTI Consulting
212-850-5683
brian.ritchie@fticonsulting.comMedia Contact:
Irma Gomez-Dib – FTI Consulting
212-850-5761
irma.gomez-dib@fticonsulting.com 

Forward-Looking Statements This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to our financial position, our estimates regarding our capital requirements and our needs for additional financing, our ability to access additional funds under the Hercules loan agreement, results of operations, the status, results and timing of results of pre-clinical studies and clinical trials and pre-clinical and clinical data described herein, the timing of and costs associated with pre-clinical studies and clinical trials, the development of our products, our estimates of the s
'/>"/>

SOURCE Insmed Incorporated
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
2. Insmed Incorporated Provides Corporate Update
3. Organogenesis Announces Annual College Scholarship Award Winner
4. Bion Announces Approval of New Canadian Patent
5. PDL BioPharma Announces Second Quarter 2012 Financial Results
6. BioPower Operations Corporation Announces that FTZ Exchange Signs Strategic Alliance with Capacity 360, LLC and Tom Settineri
7. Accuray Announces First CyberKnife System in South America
8. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
9. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
10. AMRI Announces Second Quarter 2012 Results
11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Bed bugs have become so widespread in ... many turn to chemical-based pesticides for help to completely get ... risks those solutions present, the company advised the public to ... , According to My Cleaning Products, chemical-based pesticides are ... be. It shared that the pests have already developed immunity ...
(Date:5/21/2013)... Inflamax scientists worked closely with ... design the study, which will provide critical insight ... used in the study of allergy treatments, the ... (NAC) models. Although both the models are well ... no direct comparison between the allergic responses evoked ...
(Date:5/21/2013)... SoundConnect is pleased to announce the release ... in Canada. Lync is the next generation of ... and organizations to collaborate and communicate much more easily ... the United States. With the progressive rollout of Lync ... Canada, SoundConnect now offers a complete Microsoft Lync solution ...
(Date:5/21/2013)... 2013 Clinovo's new “CDISC Standards: ... program starting on June 11th, 2013. The TechTrainings are ... reach the next step in their professional career. The ... Alto, and streamed online. , Taught by Sy Truong, ... new “CDISC Standards: Theory and Application” class will give ...
Breaking Biology Technology:New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2SoundConnect Announces Microsoft Lync Release in Canada 2SoundConnect Announces Microsoft Lync Release in Canada 3Clinovo Launches TechTrainings on CDISC Standards 2
... onset seizure reduction, proven tolerability, and ... - Keppra XR(TM) is built on ... regulated information:,UCB announced today that the U.S. Food and Drug ... as,an add-on to other antiepileptic treatments for people with partial-onset,seizures ...
... 12 Exosome Diagnostics, Inc. today,announced the appointment ... In this role, Dr. Skog will oversee the ... blood-based diagnostics that can,identify cancer-specific genetic mutations., ... of Exosome Diagnostics,core technology that has been licensed ...
... - Upfront, milestone payments and promotional investment totaling up to ... ... 12 CV Therapeutics,Inc. (Nasdaq: CVTX ) announced today ... Ranexa(R) (ranolazine prolonged release,tablets) in Europe and other countries to ...
Cached Biology Technology:Video: Keppra XR(TM) Approved in the U.S. 2Video: Keppra XR(TM) Approved in the U.S. 3Video: Keppra XR(TM) Approved in the U.S. 4CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 2CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 3CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 4CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group 5
(Date:5/20/2013)... planning grant will help establish the Center for Advanced ... University of Illinois at Urbana-Champaign and Worcester Polytechnic Institute ... to research in drying moist, porous materials such as ... chemical products; textiles; and biopharmaceuticals," said Hao Feng, a ... nutrition and the Illinois site director. , According to ...
(Date:5/20/2013)... the University of Bristol and published online today in ... on how the brain and inner ear developed in ... Earth Sciences, together with Tom Hbner from the Niederschsische ... million year old dinosaurs. , The two palaeontologists studied ... : a very young (juvenile) individual of approximately ...
(Date:5/19/2013)... white men and women of European descent inherit common ... toe deformities, including hammer or claw toe. Findings from ... of foot disorders in humansappear in Arthritis Care ... behalf of the American College of Rheumatology (ACR). ... of older adults have foot disorders which may limit ...
Breaking Biology News(10 mins):NSF approves planning grant for Center for Advanced Research in Drying 2Fossil brain teaser 2Blame your parents for bunion woes 2
... Highlights: Advanced technologies create ... Radio was integrated easily with Army,s cellular biometric network ... Harris Corporation,s (NYSE: HRS ... infrastructure for various mission scenarios at the Empire Challenge 2011 ...
... 2011 Ceelox, Inc., (OTCBB: CELO), (the "Company"), proudly ... the U.S. Patent Office. The patent, U.S. Patent Number ... Encryption And Decryption" provides the ability to biometrically enable ... data.  Ceelox, latest patent is unique in that it ...
... study from scientists at Queen Mary, University of London, sheds ... go through major surgery, can suffer organ damage in parts ... The study, published today in Nature Immunology *, ... out of blood vessels to defend damaged organs against injury ...
Cached Biology News:Harris Corporation's Highband Networking Radio Provides Mobile, Wideband Communications for Empire Challenge 2011 2Harris Corporation's Highband Networking Radio Provides Mobile, Wideband Communications for Empire Challenge 2011 3Ceelox Vault Patent Issued 2Ceelox Vault Patent Issued 3Rogue blood cells may contribute to post-surgery organ damage 2
... research laboratory, the revolutionary Luminex 100 System ... and in real time enhancing your operational ... includes the Luminex 100, the XY Platform, ... which enables you to simultaneously assay up ...
... is a compact analysis system for the clinical ... a controller, advanced digital signal processing and a ... system includes the Luminex 100, the XY Platform, ... file at the FDA, and partner kits that ...
... quality source of amino acids and ... of casein. It is recommended for ... been used in antibiotics, toxins and ... For microbiology pH6.8 0.5 at 25 ...
... peptone, used in media ... bacterial toxins, and for ... with high nutritional requirements ... Pasteurella, Salmonella and Staphylococcus ...
Biology Products: